Industries

Auto Industry

Wall Street

Stocks Extend Declines: What'd You Miss? (Full Show 9/01)

Full episode of "What'd You Miss?" Guests: Kathryn Rooney Vera, a strategist at BullTick Global Markets, BofA Merrill Lynch's Michelle Meyer, Citigroup's Steven Englander, KraneShares CIO Brendan Ahern and HSBC's Ben Laidler. (Source: Bloomberg)

Energy

Should the ECB Put More Stimulus Into Markets?

Morgan Stanley Head of Global FX Strategy Hans Redeker discusses the ECB policy decision, the Fed's decision on interest rates and the commodities market. He speaks to Bloomberg's Guy Johnson and Anna Edwards on "Countdown." (Source: Bloomberg)

Tech Opportunities: Bloomberg West (Full Show 9/01)

Full episode of "Bloomberg West." Guests: Ark Investment Managment CEO Cathie Wood, Mattermark CEO Danielle Morrill, TECHnalysis Research President Bob O'Donnell, and Ryan Wyatt, global head of gaming content at YouTube. (Source: Bloomberg)

Real Estate

Manhattan Gets First Crowdfunded Condos

New York’s first real estate project financed significantly though crowdfunding is set to open, a step forward for a nascent investing model that has yet to prove itself in commercial property.

Oil Drops

It's bad for the exporters, great news for you

Stats

700

In December, drilling contractor Ensign Energy Services Inc. told California regulators that it planned to dismiss as many as 700 workers.

Health Care

Finding a Cure in Traditional Chinese Medicine

Traditional Chinese medicine has been around for thousands of years, and now it's winning a wider audience. Patients around the world are turning to its treatments, in the hope of mitigating the side effects of Western drugs. And that means it's becoming big business, and a windfall for practitioners. Bloomberg's Juliette Saly reports. (Source: Bloomberg)

Novartis to Work With Amgen on Alzheimer’s and Migraine Drugs

Novartis AG said it formed a partnership with California biotechnology company Amgen Inc. to develop new drugs for Alzheimer’s disease and migraines, the latest step in the Swiss drugmaker’s plan to build a portfolio of treatments for neurological illnesses.